How antibody sugar structures affect lung immunity
Regulation Of Lung Immunity By Antibody Glycosylation
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11034128
This study is looking at how the sugar molecules on antibodies affect the immune response in the lungs during infections like COVID-19 and the flu, using mice that have immune systems similar to humans, to help find new ways to treat these illnesses.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11034128 on ClinicalTrials.gov |
What this research studies
This research investigates how the sugar structures on antibodies influence immune responses in the lungs, particularly during infections like COVID-19 and influenza. By studying mice that express human-like immune receptors, the researchers aim to understand how different sugar modifications on antibodies can change the way the immune system reacts to respiratory viruses. The goal is to uncover the mechanisms behind lung inflammation and how these antibody modifications can impact disease outcomes, potentially leading to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced respiratory infections, particularly those with severe cases of COVID-19 or influenza.
Not a fit: Patients with non-respiratory conditions or those who do not have a history of respiratory infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for respiratory infections by enhancing our understanding of immune responses.
How similar studies have performed: Previous research has shown that understanding antibody glycosylation can significantly impact immune responses, suggesting that this approach has potential for success.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, TAIA — STANFORD UNIVERSITY
- Study coordinator: WANG, TAIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome